细胞分化剂治疗晚期恶性肿瘤的临床观察

Therapeutic Efficacy of CDA-Ⅱ on advanced Cancer Patients:A comparison with Cytotoxic Chemotherapy

目的 探讨细胞分化剂（ＣＤＡⅡ）治疗晚期恶性肿瘤的临床疗效。方法 ４５ 例晚期恶性肿瘤患者随机分成试验组（ＣＤＡⅡ治疗）２３ 例，对照组（不用ＣＤＡⅡ）２２ 例。试验组用ＣＤＡⅡ２００ｍ ｌ加林格氏液３００ｍ ｌ加维生素Ｃ５～１０ 克静滴，每天一次，连续２０～３０ 天为一疗程：或口服ＣＤＡⅡ胶囊６～８ 粒，每天３次，一个月为一疗程。对照组不用ＣＤＡⅡ。治疗期间每周查白细胞计数。治疗前、后进行Ｔ细胞亚群测试及测定肝、肾功能。结果 近期疗效，试验组与对照组分别为６０．９％ 、３１．８％ 。试验组白细胞计数治疗前、后无明显变化，对照组有不同程度下降。试组组治疗后Ｔ细胞亚群中ＣＤ＋３ 、ＣＤ＋４ 水平明显高于对照组（Ｐ＜ ０．０１）。结论 细胞分化剂具有较强的抑瘤作用，且能提高机体的细胞免疫功能，改善生活质量，无常规化疗药物的毒副作用，为晚期恶性肿瘤病人的综合治疗提供了一种新的手段。

? Objective To investigate therapeutic efficacy of CDA Ⅱ on cancer patients.Methods 45 patients with advanced cancer were randomly divided into two groups.Experimental group with 23 cases received experimental CDA Ⅱ,and control group with 22 cases received control cytotoxic drugs.Patients in these two groups are evenly distributed with respect to sex,age,lesion sites and status of diseases.Patients in the experimental group were administrated by iv infusion of 200ml CDA Ⅱ (40mg/ml) plus 5-10g Vit.C.which were diluted with 300ml of Ringer solution.The medication was given once a day,consecutively 20-30 days a course of treatment.Some patients in this group were given CDA Ⅱ capsules.6-8 capsules (500mg/capsule)were administrated 3 times a day,consecutively 30 days a course of treatment.Patients in the control group were given only cytotoxic drugs according to protocols most effective for each leision.White blood cells and T cell subgroups were determined before and after the therapy.Liver and kidney functions were likewise carefully evaluated.Results The immediate therapeutic efficacy showed that the effective rates,namely CR plus PR,were 60.9% and 31.8% for the experimental group and the control group,respectively.White blood cells in the experimental group did not show significant difference dne to the therapy,while these cell counts were variably decreased in the control group.CD 3 and CD 4 T cell subgroups of the experimental group were significantly higher in comparison to the control group.Conclusion It is obvious that CDA Ⅱ has better therapeutic efficacy on advanced cancer patients than cytotoxic drugs.It does not produce toxic side effects normally associated with cytotoxic drugs.On the contrary,it markedly improves patients′ cell mediated immunity and quality of life.On the basis of these observations,CDA Ⅱ is highly recommended as a treatment modality of combination therapy for the advanced cancer patients. 〔